REG - Diaceutics PLC - Notice of 2021 Full Year Results

DiaceuticsAnnouncement

22/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220322:nRSV5261Fa&default-theme=true

RNS Number : 5261F  Diaceutics PLC  22 March 2022

22 March 2022

 

Diaceutics PLC

 

Notice of 2021 Full Year Results

 

Diaceutics PLC (the "Company" or the "Group"), the diagnostic
commercialisation company for precision testing, announces that due to a
short delay in the completion of the audit of its results for the year-ended
31 December 2021, these are expected to be released later today.

No changes are expected to the results outlined in the trading update
announced on the 11 January 2022.

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR
 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

 

 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDXGDXGGDDGDB